Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6462324 | 1.00 | HSD11B1 (0.39) | HSD11B1ALDH1A1SLC6A2DPP4PITRM1 | |
| SCHEMBL6922904 | 1.00 | HSD11B1 (0.39) | HSD11B1ALDH1A1SLC6A2DPP4PITRM1 | |
| SCHEMBL5521100 | 0.86 | ALOX5 (0.42) | ALDH1A1SLC6A2SLC6A3 | |
| SCHEMBL517632 | 0.84 | ALOX5 (0.41) | ALDH1A1SLC6A2SLC6A3 | |
| SCHEMBL6923366 | 0.82 | SLC6A4 (0.47) | ALDH1A1SLC6A2SLC6A3 | |
| SCHEMBL6457544 | 0.82 | SLC6A4 (0.47) | ALDH1A1SLC6A2SLC6A3 | |
| SCHEMBL6459963 | 0.80 | TSHR (0.41) | ALDH1A1DPP4DPP8 | |
| SCHEMBL6460103 | 0.80 | TSHR (0.41) | ALDH1A1DPP4DPP8 | |
| SCHEMBL515992 | 0.78 | HSD11B1 (0.36) | HSD11B1ALDH1A1 | |
| SCHEMBL6463057 | 0.76 | HIF1A (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | HSD11B1 1658/4885ALDH1A1 2036/4885SLC6A2 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.